Figure 5
Figure 5. Anti-Aspergillus fumigatus immune-response after iC9-T-cell infusion and administration of AP1903. Patient 1 entered haplo-HSCT with pulmonary Aspergillosis. (A) Fungitell levels at different times after infusion of iC9-T cells. Arrow indicates the administration of AP1903 to control acute GvHD. (B) Computed tomography scan of chest showing left upper lung lobe lesion from Aspergillus fumigatus, before iC9-T cell infusion and 24 days after infusion. Images show a decrease in size of the largest nodule within the left upper lobe (left) at 24 days after iC9-T-cell infusion with a loss of cavitary appearance (right). (C) Detection of Aspergillus fumigatus specific T-cells by intracellular IFN-γ release from both CD3+CD19+ and CD3+CD19− T cells in samples collected at different times after AP1903 administration.

Anti-Aspergillus fumigatus immune-response after iC9-T-cell infusion and administration of AP1903. Patient 1 entered haplo-HSCT with pulmonary Aspergillosis. (A) Fungitell levels at different times after infusion of iC9-T cells. Arrow indicates the administration of AP1903 to control acute GvHD. (B) Computed tomography scan of chest showing left upper lung lobe lesion from Aspergillus fumigatus, before iC9-T cell infusion and 24 days after infusion. Images show a decrease in size of the largest nodule within the left upper lobe (left) at 24 days after iC9-T-cell infusion with a loss of cavitary appearance (right). (C) Detection of Aspergillus fumigatus specific T-cells by intracellular IFN-γ release from both CD3+CD19+ and CD3+CD19 T cells in samples collected at different times after AP1903 administration.

Close Modal

or Create an Account

Close Modal
Close Modal